The ESSENCE trial, a phase III clinical trial, demonstrated the efficacy of once-weekly semaglutide in treating metabolic dysfunction–associated steatohepatitis with liver fibrosis. Results showed significant improvement in hepatic histologic endpoints and other markers of liver health over 72 weeks. The study authors indicated a notable resolution of steatohepatitis, reduction in liver fibrosis, weight loss, and positive effects on glycemia and insulin resistance.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
